Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Appelt

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Current Eye Research|September 12, 2000
The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathyU Ozerdem, B Mach-Hofacre, L Cheng, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1996
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus proteaseA K Patick, H Mo, M Markowitz, et al.
Journal of Medicinal Chemistry|July 22, 1994
Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV proteaseM D Varney, K Appelt, V Kalish, et al.
Journal of Medicinal Chemistry|July 5, 1996
Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide seriesS H Reich, M Melnick, M J Pino, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 1995
Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus proteaseS H Reich, M Melnick, J F Davies, et al.
Annals of the New York Academy of Sciences|July 23, 1999
Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trialsD R Shalinsky, J Brekken, H Zou, et al.
Journal of Medicinal Chemistry|July 1, 1991
Design of enzyme inhibitors using iterative protein crystallographic analysisK Appelt, R J Bacquet, C A Bartlett, et al.
Structure (London, England : 1993)|June 16, 1999
Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesisM A McTigue, J A Wickersham, C Pinko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 1999
Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340A Price, Q Shi, D Morris, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 5, 2001
Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbitL Cheng, M E Rivero, C R Garcia, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Current Eye Research|September 12, 2000
The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathyU Ozerdem, B Mach-Hofacre, L Cheng, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1996
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus proteaseA K Patick, H Mo, M Markowitz, et al.
Journal of Medicinal Chemistry|July 22, 1994
Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV proteaseM D Varney, K Appelt, V Kalish, et al.
Journal of Medicinal Chemistry|July 5, 1996
Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide seriesS H Reich, M Melnick, M J Pino, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 1995
Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus proteaseS H Reich, M Melnick, J F Davies, et al.
Annals of the New York Academy of Sciences|July 23, 1999
Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trialsD R Shalinsky, J Brekken, H Zou, et al.
Journal of Medicinal Chemistry|July 1, 1991
Design of enzyme inhibitors using iterative protein crystallographic analysisK Appelt, R J Bacquet, C A Bartlett, et al.
Structure (London, England : 1993)|June 16, 1999
Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesisM A McTigue, J A Wickersham, C Pinko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 1999
Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340A Price, Q Shi, D Morris, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 5, 2001
Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbitL Cheng, M E Rivero, C R Garcia, et al.
Pageof 6